Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities

Emma M. Kerr, Edoardo Gaude, Frances K. Turrell, Christian Frezza and Carla P. Martins ()
Additional contact information
Emma M. Kerr: MRC Cancer Unit, University of Cambridge
Edoardo Gaude: MRC Cancer Unit, University of Cambridge
Frances K. Turrell: MRC Cancer Unit, University of Cambridge
Christian Frezza: MRC Cancer Unit, University of Cambridge
Carla P. Martins: MRC Cancer Unit, University of Cambridge

Nature, 2016, vol. 531, issue 7592, 110-113

Abstract: Mutant Kras lung tumours are not a single disease but comprise two classes of tumours with distinct metabolic profiles, prognosis and therapeutic susceptibility, which can be discriminated by their relative mutant Kras allelic content.

Date: 2016
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature16967 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:531:y:2016:i:7592:d:10.1038_nature16967

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature16967

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().